| Literature DB >> 27299567 |
Elizabeth W Paxton1, Andy Torres1, Rebecca M Love1, Thomas C Barber2, Dhiren S Sheth3, Maria C S Inacio1,4.
Abstract
Background and purpose - The effect of total joint arthroplasty (TJA) on physical activity is not fully understood. We investigated the change in physical activity after TJA and patient factors associated with change. Patients and methods - Using a total joint replacement registry, primary total hip arthroplasty (THA) patients (n = 5,678) and knee arthroplasty (TKA) patients (n = 11,084) between January 1, 2010 and December 31, 2012 were identified. Median age at THA was 68 and median age at TKA was 67. Change in self-reported physical activity (minutes per week) from before TJA (within 1 year of surgery) to after TJA (1-2 years) was the outcome of interest. Patient demographics and comorbidities were evaluated as risk factors. Multiple linear regression was used. Results - Median physical activity before surgery was 50 min/week (IQR: 0-140) for THA patients and 58 (IQR: 3-143) for TKA patients. Median physical activity after surgery was 150 min/week (IQR: 60-280) for both THA patients and TKA patients. Following TJA, 50% of patients met CDC/WHO physical activity guideline criteria. Higher body mass index was associated with lower change in physical activity (THA: -7.1 min/week; TKA: -5.9 min/week). Females had lower change than males (THA: -11 min/week; TKA: -9.1 min/week). In TKA patients, renal failure was associated with lower change (-17 min/week), as were neurological disorders (-30 min/week). Interpretation - Self-reported minutes of physical activity increased from before to after TJA, but 50% of TJA patients did not meet recommended physical activity guideline criteria. Higher body mass index, female sex, and specific comorbidities were found to be associated with low change in physical activity. Patient education on the benefits of physical activity should concentrate on these subgroups of patients.Entities:
Mesh:
Year: 2016 PMID: 27299567 PMCID: PMC4937772 DOI: 10.1080/17453674.2016.1193663
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Characteristics of the study sample and change in physical activity from before to after total joint arthroplasty, according to patient characteristics. Physical activity (PA) values are median and IQR minutes per week
| THA | TKA | |||||||
|---|---|---|---|---|---|---|---|---|
| n (%) | PA prior to surgery | PA post to surgery | Change in PA | n (%) | PA prior to surgery | PA post to surgery | Change in PA | |
| Total | 5,678 | 50 (0–140) | 150 (60–280) | 70 (0–170) | 11,084 | 58 (3–143) | 150 (60–280) | 76 (0–179) |
| Sex | ||||||||
| Female | 3,323 (59) | 41 (0–120) | 150 (40–240) | 68 (0–156) | 6,861 (62) | 45 (0–120) | 150 (60–240) | 74 (0–165) |
| Male | 2,355 (41) | 64 (0–173) | 180 (60–300) | 75 (0–190) | 4,223 (38) | 80 (15–180) | 180 (80–300) | 80 (0–198) |
| Age, median (IQR) | 67 (60–75) | 68 (62–75) | ||||||
| Age category | ||||||||
| Age <55 | 666 (12) | 57 (0–150) | 150 (40–300) | 60 (0–180) | 788 (7) | 60 (2–148) | 150 (60–270) | 76 (0–180) |
| Age ≥55 | 5,012 (88) | 50 (0–140) | 150 (60–280) | 70 (0–169) | 10,296 (93) | 57 (3–142) | 150 (60–280) | 76 (0–178) |
| BMI, median (IQR) | 28 (25–32) | 30 (27–34) | ||||||
| BMI category | ||||||||
| < 30 | 3,519 (62) | 68 (0–165) | 180 (60–300) | 70 (0–180) | 5,393 (49) | 75 (15–173) | 180 (90–300) | 80 (0–180) |
| ≥ 30 and <35 | 1,407 (25) | 33 (0–120) | 150 (30–240) | 70 (0–166) | 3,361 (30) | 50 (0–126) | 150 (60–250) | 73 (0–178) |
| ≥ 35 | 752 (13) | 17 (0–70) | 120 (0–210) | 60 (0–150) | 2,324 (21) | 30 (0–95) | 120 (20–210) | 66 (0–164) |
| Race | ||||||||
| White | 4,310 (76) | 52 (0–150) | 150 (60–280) | 70 (0–168) | 7,001 (63) | 63 (4–151) | 150 (60–300) | 72 (0–175) |
| Hispanic | 586 (10) | 34 (0–100) | 150 (50–240) | 90 (0–180) | 2,170 (20) | 45 (1–116) | 150 (60–270) | 83 (0–180) |
| Black | 512 (9) | 40 (0–115) | 150 (60–290) | 77 (0–180) | 1,035 (9) | 42 (3–108) | 150 (60–250) | 77 (0–180) |
| Asian | 187 (3) | 75 (7–150) | 150 (30–300) | 50 (0–153) | 682 (6) | 69 (10–146) | 180 (70–280) | 75 (0–175) |
| Other | 57 (1) | 48 (0–138) | 200 (80–360) | 120 (14–210) | 135 (1) | 40 (0–150) | 150 (20–270) | 80 (0–158) |
| Unknown | 26 (0.5) | 52 (8–107) | 150 (40–250) | 26 (–30–150) | 61 (0.6) | 40 (0–138) | 180 (60–300) | 80 (0–180) |
| Diabetes | 1,074 (19) | 31 (0–100) | 140 (30–240) | 70 (0–163) | 3,022 (27) | 42 (0–120) | 140 (60–250) | 70 (0–175) |
| Comorbidity | ||||||||
| Congestive heart failure | 129 (2) | 10 (0–82) | 70 (0–210) | 30 (0–167) | 260 (2) | 34 (0–120) | 140 (40–270) | 80 (0–194) |
| Valvular disease | 203 (4) | 54 (0–140) | 150 (30–300) | 90 (0–180) | 347 (3) | 60 (3–152) | 160 (70–280) | 75 (0–165) |
| Pulmonary circulation disease | 39 (0.7) | 15 (0–105) | 100 (0–300) | 30 (0–210) | 59 (0.5) | 39 (0–110) | 100 (40–250) | 56 (0–200) |
| Peripheral vascular disease | 424 (8) | 35 (0–135) | 140 (0–275) | 55 (0–180) | 776 (7.0) | 45 (1–120) | 150 (50–280) | 82 (0–177) |
| Paralysis | 24 (0.4) | 45 (0–130) | 90 (0–225) | 0 (–29–115) | 58 (0.5) | 15 (0–85) | 60 (0–210) | 35 (0–120) |
| Other neurological disorders | 142 (3) | 45 (0–120) | 120 (40–210) | 60 (0–140) | 319 (3) | 41 (0–133) | 140 (0–210) | 50 (0–140) |
| Chronic pulmonary disease | 744 (13) | 35 (0–120) | 140 (40–260) | 70 (0–170) | 1,561 (14) | 47 (0–120) | 150 (50–240) | 70 (0–172) |
| Hypothyroidism | 658 (12) | 40 (0–121) | 150 (20–240) | 60 (0–159) | 1,398 (13) | 52 (4–140) | 150 (60–240) | 70 (0–160) |
| Renal failure | 486 (9) | 23 (0–92) | 120 (10–210) | 56 (0–144) | 1,151 (10) | 39 (0–120) | 120 (40–210) | 61 (0–150) |
| Liver disease | 111 (2) | 55 (0–173) | 180 (60–360) | 80 (0–180) | 252 (2) | 53 (4–145) | 150 (50–240) | 63 (0–150) |
| Peptic ulcer | 0 (0) | – | – | – | 3 (0.0) | 0 (0–70) | 70 (0–210) | 70 (0–140) |
| AIDS | 8 (0.1) | 104 (45–155) | 435 (270–735) | 280 (150–632) | 5 (0.0) | 13 (0–316) | 450 (450–600) | 284 (107–450) |
| Lymphoma | 21 (0.4) | 60 (23–150) | 180 (70–360) | 30 (0–230) | 25 (0.2) | 35 (17–160) | 140 (0–210) | 40 (–17–140) |
| Metastatic cancer | 19 (0.3) | 98 (20–208) | 160 (0–270) | 50 (–20–150) | 25 (0.2) | 20 (0–60) | 210 (90–300) | 129 (0–240) |
| Solid tumor w/o metastasis | 58 (1) | 19 (0–120) | 155 (40–360) | 120 (0–210) | 105 (0.9) | 65 (15–130) | 150 (90–280) | 77 (20–180) |
| Rheumatoid arthritis | 161 (3) | 27 (0–110) | 120 (10–210) | 60 (0–144) | 305 (3) | 47 (0–120) | 150 (70–270) | 83 (0–180) |
| Coagulopathy | 109 (2) | 63 (0–150) | 140 (0–280) | 30 (–1–145) | 195 (2) | 56 (6–120) | 120 (20–280) | 53 (–10–151) |
| Weight loss | 48 (0.8) | 5 (0–62) | 145 (15–280) | 80 (0–225) | 78 (0.7) | 47 (8–135) | 150 (60–280) | 91 (0–210) |
| Fluid and electrolyte disorders | 304 (5) | 35 (0–120) | 150 (50–275) | 83 (0–178) | 635 (6) | 60 (7–150) | 150 (60–280) | 80 (0–177) |
| Chronic blood loss anemia | 169 (3) | 17 (0–72) | 120 (30–240) | 90 (0–160) | 395 (4) | 51 (10–120) | 180 (70–300) | 98 (1–184) |
| Deficiency anemias | 586 (10) | 35 (0–112) | 145 (40–250) | 79 (0–180) | 1,137 (10) | 49 (0–125) | 150 (60–250) | 76 (0–169) |
| Alcohol abuse | 119 (2) | 35 (0–119) | 150 (20–300) | 61 (0–168) | 197 (2) | 60 (12–160) | 160 (60–280) | 64 (0–154) |
| Drug abuse | 76 (1) | 8 (0–70) | 140 (0–275) | 70 (0–185) | 97 (0.9) | 53 (0–148) | 150 (20–240) | 44 (–1–147) |
| Psychoses | 403 (7) | 30 (0–105) | 120 (0–210) | 48 (0–137) | 857 (8) | 41 (0–118) | 150 (40–240) | 70 (0–159) |
| Depression | 259 (5) | 30 (0–124) | 150 (20–270) | 77 (0–188) | 561 (5) | 43 (0–120) | 150 (60–240) | 73 (0–179) |
| Hypertension | 2,957 (52) | 39 (0–120) | 150 (40–250) | 70 (0–160) | 6,494 (59) | 50 (0–135) | 150 (60–270) | 73 (0–173) |
THA: total hip arthroplasty; TKA: total knee arthroplasty; BMI: body mass index; AIDS: acquired immunodeficiency syndrome; PA: physical activity; IQR: interquartile range.
Missing data: comorbidity indicators (13.2%, n = 752) in THA cases; BMI (0.1%, n = 6) and comorbidity indicators (15.1%, n = 1,678) in TKA.
Risk factors associated with change in physical activity according to multiple linear regression and p-values — total hip athroplasty
| Parameter Level | Crude | p–value | Adjusted | p–value |
|---|---|---|---|---|
| Sex | ||||
| Male | Ref. | – | Ref. | – |
| Female | –10 (–15 to –5) | 0.06 | –11 (–17 to –5) | 0.07 |
| Age per 5-year increment | –1.5 (–3 to –0.3) | 0.2 | –0.7 (–2 to 0.9) | 0.7 |
| BMI per 5-unit increment | –4.2 (–7 to –2) | 0.09 | –7.1 (–10 to –4) | 0.02 |
| Race | ||||
| White | Ref. | – | Ref. | – |
| Hispanic | 18 (9 to 27) | 0.04 | 18 (8 to 27) | 0.06 |
| Black | 15 (6 to 24) | 0.1 | 13 (3 to 23) | 0.2 |
| Asian | –20 (–34 to –5) | 0.2 | –27 (–42 to –11) | 0.09 |
| Other | 57 (30 to 83) | 0.03 | 73 (43 to 103) | 0.02 |
| Unknown | –8.5 (–47 to 30) | 0.8 | –52 (–127 to 23) | 0.5 |
| Diabetes | 6.6 (–0.1 to 13) | 0.3 | 11 (3 to 19) | 0.2 |
| Comorbidity | ||||
| Congestive heart failure | 6.5 (–11 to 24) | 0.7 | 7.6 (–11 to 26) | 0.7 |
| Valvular disease | –3.7 (–18 to 11) | 0.8 | –3.8 (–19 to 11) | 0.8 |
| Pulmonary circulation disease | 13 (–19 to 45) | 0.7 | 21 (–13 to 54) | 0.5 |
| Peripheral vascular disease | –9.2 (–19 to 1) | 0.4 | –9.9 (–20 to 0.6) | 0.3 |
| Paralysis | –60 (–19 to 101) | 0.1 | –58 (–99 to –17) | 0.2 |
| Other neurological disorders | –27 (–44 to –10) | 0.1 | –23 (–41 to –6) | 0.2 |
| Chronic pulmonary disease | 2.5 (–6 to 11) | 0.8 | 6.7 (–1 to 15) | 0.4 |
| Hypothyroidism | –11 (–19 to –2) | 0.2 | –4.4 (–13 to 4) | 0.6 |
| Renal failure | –17 (–27 to –8) | 0.08 | –14 (–24 to –4) | 0.1 |
| Liver disease | 21 (2–40) | 0.3 | 16 (–4 to 35) | 0.4 |
| Peptic ulcer | – | – | – | – |
| AIDS | 238 (166 to 310) | 0.001 | 224 (152 to 297) | 0.002 |
| Lymphoma | 29 (–14 to 73) | 0.5 | 15 (–29 to 58) | 0.7 |
| Metastatic cancer | –49 (–95 to –3) | 0.3 | –46 (–92 to –0.6) | 0.3 |
| Solid tumor w/o metastasis | 54 (27 to 80) | 0.04 | 52 (25 to 78) | 0.05 |
| Rheumatoid arthritis | 3.4 (–13 to 20) | 0.8 | 5 (–11 to 21) | 0.8 |
| Coagulopathy | –10 (–29 to 9) | 0.6 | –16 (–36 to 3) | 0.4 |
| Weight loss | 36 (7 to 64) | 0.2 | 27 (–2 to 56) | 0.4 |
| Fluid and electrolyte disorders | 8.1 (–4 to 20) | 0.5 | 12 (0.2 to 24) | 0.3 |
| Chronic blood loss anemia | 5.7 (–10 to 21) | 0.7 | 8 (–8 to 24) | 0.6 |
| Deficiency anemias | 24 (15 to 32) | 0.01 | 25 (17 to 34) | 0.004 |
| Alcohol abuse | 13. (–5 to 32) | 0.5 | 16 (–3 to 35) | 0.4 |
| Drug abuse | 6.7 (–16 to 30) | 0.8 | 4.2 (–19 to 28) | 0.9 |
| Psychoses | –40 (–52 to –28) | 0.001 | –38 (–50 to –27) | 0.001 |
| Depression | 7.2 (–5 to 20) | 0.6 | 4.9 (–8 to 18) | 0.7 |
| Hypertension | –8.3 (–14 to –3) | 0.2 | –6 (–12 to 0.4) | 0.3 |
BMI: body mass index; AIDS: acquired immunodeficiency syndrome.
Crude models, n = 5,678; adjusted model, n = 4,926, due to n = 752 (13.2%) missing comorbidity data.
Risk factors associated with change in physical activity according to multiple linear regression and p-values ― total knee arthroplasty
| Parameter Level | Crude | p–value | Adjusted | p–value |
|---|---|---|---|---|
| Sex | ||||
| Male | Ref. | – | Ref. | – |
| Female | –9.5 (–13 to –6) | 0.01 | –9.1 (–13 to –5) | 0.04 |
| Age per 5–year increment | –0.9 (–2 to 0.1) | 0.36 | –2.3 (–4 to –1) | 0.06 |
| BMI per 5–unit increment | –3.2 (–5 to –2) | 0.05 | –5.9 (–8 to –4) | 0.003 |
| Race | ||||
| White | Ref. | – | Ref. | – |
| Hispanic | 13 (9 to 18) | 0.005 | 16 (11 to 22) | 0.002 |
| Black | 9.5 (3 to 16) | 0.1 | 14 (7 to 21) | 0.04 |
| Asian | –6.6 (–14 to 1) | 0.4 | –8.9 (–17 to –0.7) | 0.3 |
| Other | –7.2 (–38 to 24) | 0.8 | 11 (–8 to 30) | 0.6 |
| Unknown | 15 (–10 to 40) | 0.5 | –59 (–104 to –13) | 0.2 |
| Diabetes | 2.6 (–2 to 7) | 0.5 | 3.4 (–1 to 8) | 0.4 |
| Comorbidity | ||||
| Congestive heart failure | 5.8 (–6 to 18) | 0.6 | 10 (–2 to 22) | 0.4 |
| Valvular disease | –3.6 (–14 to 7) | 0.7 | –0.2 (–13 to 12) | 0.9 |
| Pulmonary circulation disease | 3.1 (–22 to 28) | 0.9 | 8.1 (–18 to 34) | 0.8 |
| Peripheral vascular disease | 9.7 (3–17) | 0.2 | 12 (5 to 20) | 0.1 |
| Paralysis | 2.8 (–23 to 28) | 0.9 | 6.5 (–19 to 32) | 0.8 |
| Other neurological disorders | –31 (–42 to –20) | 0.004 | –30 (–41 to –19) | 0.006 |
| Chronic pulmonary disease | –2 (–7 to 3) | 0.7 | 2 (–4 to 7) | 0.7 |
| Hypothyroidism | –9 (–15 to –4) | 0.1 | –3.7 (–9 to 2) | 0.5 |
| Renal failure | –17 (–23 to –11) | 0.005 | –17 (–23 to –10) | 0.009 |
| Liver disease | –15 (–27 to –3) | 0.2 | –17 (–29 to –4) | 0.2 |
| Peptic ulcer | –33 (–144 to 78) | 0.8 | –37 (–148 to 75) | 0.7 |
| AIDS | 204 (117 to 290) | 0.02 | 201 (287 to 114) | 0.02 |
| Lymphoma | 25 (–13 to 64) | 0.5 | 26 (–13 to 64) | 0.5 |
| Metastatic cancer | 70 (32 to 109) | 0.07 | 74 (34 to 112) | 0.06 |
| Solid tumor w/o metastasis | 4 (–15 to 23) | 0.8 | 4.1 (–15 to 23) | 0.8 |
| Rheumatoid arthritis | –2.6 (–14 to 9) | 0.8 | –1.1 (–13 to 10) | 0.9 |
| Coagulopathy | –12 (–26 to 2) | 0.4 | –12 (–26 to 2) | 0.4 |
| Weight loss | 29 (7 to 51) | 0.2 | 32 (10 to 54) | 0.2 |
| Fluid and electrolyte disorders | 0.2 (–6 to 7) | 0.9 | 0.6 (–8 to 9) | 0.9 |
| Chronic blood loss anemia | 25 (15 to 35) | 0.01 | 27 (17 to 37) | 0.007 |
| Deficiency anemias | 2.4 (–4 to 9) | 0.7 | 2.9 (–3 to 9) | 0.7 |
| Alcohol abuse | –10 (–24 to 4) | 0.5 | –8.9 (–23 to 5) | 0.5 |
| Drug abuse | –29 (–48 to –9) | 0.2 | –30 (–50 to –10) | 0.1 |
| Psychoses | –6.9 (–14 to 0.0) | 0.3 | –3.7 (–11 to 3) | 0.6 |
| Depression | –3.7 (–12 to 5) | 0.7 | –2.4 (–11 to 6) | 0.8 |
| Hypertension | –1.7 (–6 to 3) | 0.7 | 2.2 (–2 to 7) | 0.6 |
BMI: body mass index; AIDS: acquired immunodeficiency syndrome.
Crude models, n = 11,084; adjusted model, n = 9,402 due to n = 1,682 (15.1%) missing comorbidity data and n = 6 (0.1%) missing BMI data.